<DOC>
	<DOCNO>NCT01343043</DOCNO>
	<brief_summary>The purpose early ( pilot ) clinical trial test effect ( good bad ) chemotherapy adoptive immunotherapy T cell engineer recognize NY-ESO-1 peptide patient unresectable , metastatic recurrent synovial sarcoma .</brief_summary>
	<brief_title>A Pilot Study Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T HLA-A2+ Patients With Synovial Sarcoma</brief_title>
	<detailed_description>Design - Patients undergo apheresis enrol institution . PBMC ship central manufacturer gene transduction , activation expansion , cryopreserved ship back enrol institution . - The trial seek enroll 65 patient , , 20 patient Cohort 1 15 patient Cohorts 2-4 . Depending cohort patient enrol , patient undergo lymphodepletion cyclophosphamide without fludarabine . - Cohort 1 : Complete - Cohort 2 : Up 15 patient may enrol achieve least 10 evaluable patient treat NY-ESO-1ᶜ²⁵⁹T . Patients undergo lymphodepletion cyclophosphamide plus fludarabine Days -3 -2 , without fludarabine Days -5 -4 . - Cohort 3 : Up 15 patient may enrol achieve least 10 evaluable patient treat NY-ESO-1ᶜ²⁵⁹T . Patients undergo lymphodepletion cyclophosphamide Days -3 -2 . ( Cohort Complete ) - Cohort 4 : Up 15 patient may enrol achieve least 5 evaluable patient treat NY-ESO-1ᶜ²⁵⁹T . Patients undergo lymphodepletion cyclophosphamide plus fludarabine Days -7 -5 . On Day 0 , patient ≥40 kg receive minimum cell dose least 1x10⁹ transduced NY-ESO-1ᶜ²⁵⁹T cell maximum 6x10⁹ transduced cell . The target dose protocol 5x10⁹ transduce NY-ESO-1ᶜ²⁵⁹T cell . Patients &lt; 40 kg dose per body weight minimum 0.025x10⁹ transduced cells/kg , target dose 0.125 x10⁹ transduce cells/kg . - Patients monitored toxicity , antitumor effect immune endpoint . - Patients confirm response , stable disease &gt; 3 month progress may receive 2nd T cell infusion , provide eligibility criterion meet . The 2nd treatment cell infusion administer manner first . Patients meet eligibility criterion may receive 2nd infusion NY-ESO-1ᶜ²⁵⁹T sooner 60 day later 2 year follow completion first treatment .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Synovial</mesh_term>
	<criteria>Synovial sarcoma treat standard chemotherapy contain ifosfamide and/or doxorubicin remain : unresectable metastatic progressive/persistent recurrent disease Measurable disease Patients must prove positive tumor sample NYESO1 follow : Cohort 1 Positive expression define 2+ and/or 3+ immunohistochemistry ≥ 50 % cell . Cohort 2 Positive expression define ≥1+ immunohistochemistry ≥1 % cell , exceed 2+ and/or 3+ ≥ 50 % cell . Cohort 3 Positive expression define 2+ and/or 3+ immunohistochemistry ≥ 50 % cell . Cohort 4 Positive expression define 2+ and/or 3+ immunohistochemistry ≥ 50 % cell . HLAA*02:01 , HLAA*02:05 , and/or HLAA*02:06 high resolution test local central laboratory Weigh 18 kg All previous cytotoxic chemotherapy , monoclonal antibody therapy , immune therapy must wash 3 week apheresis must complete least 3 week prior preinfusion lymphodepletive chemotherapy . Systemic corticosteroid immunosuppressive therapy wash 2 week apheresis must complete least 2 week prior preinfusion lymphodepletive chemotherapy . Biologic approve molecular target small molecule inhibitor wash 1 week 5 halflives ( whichever longer ) apheresis must complete least 1 week 5 halflives ( whichever longer ) prior preinfusion lymphodepletive chemotherapy . Any grade 3 4 hematologic toxicity previous therapy must resolve grade 2 less prior apheresis grade 3 4 toxicity must resolve grade 2 less prior preinfusion lymphodepletive chemotherapy . ECOG 01 , child ≤10 year age , Lansky &gt; 60 Life expectancy &gt; 3 month Left ventricular ejection fraction ≥ 40 % fractional shortening ≥ 28 % T. bilirubin &lt; 2 mg/dl ( Patients Gilbert Syndrome total bilirubin &lt; 3xULN direct bilirubin ≤ 35 % ) AST , ALT ≤ 2.5 x upper limit normal ANC ≥ 1.0 x 10⁹/L Platelets ≥ 75 x 10⁹/L Ageadjusted normal serum creatinine creatinine clearance ≥ 40 ml/min Ability give inform consent patient great 18 year age . For patient le 18 year age legal guardian must give informed consent . Male patient must willing practice birth control ( include abstinence ) 4 month treatment . Female patient must willing practice birth control ( include abstinence ) treatment 4 month gene modify cell longer detect body . Active HIV , HBV , HCV HTLV 1/2 infection ( due increase risk complication lymphodepleting regimen confound effect immune system ) . Active hepatitis B C infection define seropositive hepatitis B surface antigen ( HbSAg ) hepatitis C antibody .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Sarcoma</keyword>
	<keyword>Cell Therapy</keyword>
	<keyword>T Cell Therapy</keyword>
	<keyword>NY-ESO-1</keyword>
	<keyword>Immuno-oncology</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Previously treat</keyword>
	<keyword>T Cell Receptor</keyword>
</DOC>